Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib IMAGE OF THE MONTH Diffuse Hemorrhagic Brain Metastases in an ALK Fusion  Positive Patient on Crizotinib Kevin Jao, MD, MSc, FRCPC, Pascale Tomasini, MD, MSc, Catherine Labbe, MD, Mark Doherty, MD, and Frances A. Shepherd, MD, FRCPC 52-year-old woman and lifetime nonsmoker was pre- inhibitors. Interestingly, our patient presented with dif- A sented initially with pleuritic chest pain. Investigations fuse hemorrhagic metastases. The incidence of spontaneous revealed a small lower left lobe nodule, extensive intratho- intracranial hemorrhage in patients with non–small-cell lung racic lymphadenopathy, and a large adnexal lesion. Her cancer (NSCLC) with brain metastasis is estimated at 1.2%. initial brain magnetic resonance imaging was negative. There are no published reports of intracranial hemorrhage Biopsies revealed an adenocarcinoma, TTF-1 positive com- in patients with ALK-positive NSCLC treated with crizo- patible with a primary lung carcinoma. Molecular testing tinib. A recent Children’s Oncology Group trial evaluated was negative for epidermal growth factor receptor muta- single agent crizotinib in pediatric oncology patients with tions, but immunohistochemical staining revealed positiv- refractory solid tumors. Two patients with primary CNS XXX ity for ELM4-ALK fusion, which was confirmed by FISH. tumors developed intratumoral hemorrhages which were After failing standard chemotherapy, crizotinib was initi- deemed possibly related to crizotinib. Subsequently, the trial ated as second-line http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib

Journal of Thoracic Oncology , Volume 10 (6) – Jun 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/diffuse-hemorrhagic-brain-metastases-in-an-alk-fusion-positive-patient-ImHLmJsxlS

References (10)

Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000403
pmid
26001146
Publisher site
See Article on Publisher Site

Abstract

IMAGE OF THE MONTH Diffuse Hemorrhagic Brain Metastases in an ALK Fusion  Positive Patient on Crizotinib Kevin Jao, MD, MSc, FRCPC, Pascale Tomasini, MD, MSc, Catherine Labbe, MD, Mark Doherty, MD, and Frances A. Shepherd, MD, FRCPC 52-year-old woman and lifetime nonsmoker was pre- inhibitors. Interestingly, our patient presented with dif- A sented initially with pleuritic chest pain. Investigations fuse hemorrhagic metastases. The incidence of spontaneous revealed a small lower left lobe nodule, extensive intratho- intracranial hemorrhage in patients with non–small-cell lung racic lymphadenopathy, and a large adnexal lesion. Her cancer (NSCLC) with brain metastasis is estimated at 1.2%. initial brain magnetic resonance imaging was negative. There are no published reports of intracranial hemorrhage Biopsies revealed an adenocarcinoma, TTF-1 positive com- in patients with ALK-positive NSCLC treated with crizo- patible with a primary lung carcinoma. Molecular testing tinib. A recent Children’s Oncology Group trial evaluated was negative for epidermal growth factor receptor muta- single agent crizotinib in pediatric oncology patients with tions, but immunohistochemical staining revealed positiv- refractory solid tumors. Two patients with primary CNS XXX ity for ELM4-ALK fusion, which was confirmed by FISH. tumors developed intratumoral hemorrhages which were After failing standard chemotherapy, crizotinib was initi- deemed possibly related to crizotinib. Subsequently, the trial ated as second-line

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2015

There are no references for this article.